GSK/HGS win US FDA OK for raxibacumab as 1st mAb in anthrax

GlaxoSmithKline and its subsidiary Human Genome Sciences not only won the US FDA's OK to market raxibacumab in combination with antibacterials as a treatment for adults and pediatric patients with inhalational anthrax, the companies also were granted approval to sell the medicine as a preventive therapy when alternative treatments are not available or appropriate.